Rocheusa ( Rocheusa )

Rocheusa

Rocheusa's picture

Roche AG is a Swiss multinational health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.

Rocheusa press release, blog etc

05/16/2018 - 20:22 Follow-up phase III data showed Roches Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death
05/13/2018 - 22:35 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress
05/10/2018 - 02:35 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
05/08/2018 - 01:36 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
05/06/2018 - 22:43 FDA grants priority review to Roches cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
04/27/2018 - 09:12 CHMP recommends EU approval of Roches Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
04/25/2018 - 21:03 Roche reports a strong start in 2018
04/16/2018 - 23:26 FDA grants Breakthrough Therapy Designation for Roches Hemlibra in haemophilia A without inhibitors
04/16/2018 - 02:52 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
04/06/2018 - 01:40 Roche completes acquisition of Flatiron Health
03/27/2018 - 22:30 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
03/26/2018 - 05:23 Phase III IMpower150 study showed Roches TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
03/13/2018 - 07:15 Roche Annual General Meeting 2018
03/08/2018 - 01:07 Changes to the Roche Enlarged Corporate Executive Committee
02/27/2018 - 10:38 European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
02/15/2018 - 12:08 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
02/07/2018 - 23:23 Roche purchases shares in tender offer for Ignyta, Inc.
02/06/2018 - 00:05 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer